Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026

Incyte (INCY)

Nasdaq Health Care Biotechnology S&P 500
$119.65
+1.64 (+1.39%)
Close of Nov 06, 2026 · end-of-day data
Source: Incyte's 10-K / 10-Q XBRL data on SEC EDGAR · fetched Nov 06, 2026

Revenue, net income & free cash flow

Income statement

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue$1.11B$1.54B$1.88B$2.16B$2.67B$2.99B$3.39B$3.70B$4.24B$5.14B
Cost of revenue$58.19M$79.48M$94.12M$114.25M$131.33M$150.99M$207.00M$254.99M$312.07M$372.13M
Gross profit$1.05B$1.46B$1.79B$2.04B$2.54B$2.84B$3.19B$3.44B$3.93B$4.77B
Research & development$581.86M$1.33B$1.20B$1.15B$2.22B$1.46B$1.59B$1.63B$2.61B$2.05B
Selling, general & admin$303.25M$366.29M$434.41M$468.71M$516.92M$739.56M$1.00B$1.16B$1.24B$1.38B
Operating income$145.00M-$243.39M$129.22M$402.01M-$263.68M$585.78M$579.44M$620.52M$61.37M$1.51B
Interest expense$38.74M$6.90M$1.54M$1.85M$2.17M$1.91M$2.67M$2.55M$2.28M$2.43M
Pre-tax income$107.40M-$312.29M$115.35M$486.79M-$232.22M$570.44M$529.12M$834.22M$316.63M$1.66B
Income tax$3.18M$852.00K$5.85M$39.88M$63.48M-$378.14M$188.46M$236.62M$284.01M$377.80M
Net income$104.22M-$313.14M$109.49M$446.91M-$295.70M$948.58M$340.66M$597.60M$32.62M$1.29B
EBITDA$203.42M-$191.21M$184.19M$456.54M-$211.87M$643.62M$647.29M$703.18M$150.61M$1.61B
EPS (basic)$0.55$-1.53$0.52$2.08$-1.36$4.30$1.53$2.67$0.16$6.59
EPS (diluted)$0.54$-1.53$0.51$2.05$-1.36$4.27$1.52$2.65$0.15$6.41
Diluted shares194.12M204.58M215.63M217.66M218.07M222.07M223.96M225.93M210.53M200.70M
Gross margin94.7%94.8%95.0%94.7%95.1%94.9%93.9%93.1%92.6%92.8%
Operating margin13.1%-15.8%6.9%18.6%-9.9%19.6%17.1%16.8%1.4%29.5%
Net margin9.4%-20.4%5.8%20.7%-11.1%31.8%10.0%16.2%0.8%25.0%

Balance sheet

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash & equivalents$652.34M$899.51M$1.16B$1.83B$1.51B$2.06B$2.95B$3.21B$1.69B$3.10B
Short-term investments$156.20M$270.14M$274.34M$284.87M$288.37M$290.75M$287.54M$442.67M——
Inventory$4.11M$6.48M$6.97M$11.40M$16.43M$27.90M$41.99M$62.97M$58.87M$101.06M
Total current assets$994.18M$1.50B$1.83B$2.48B$2.36B$3.12B$4.09B$4.65B$3.24B$5.02B
Goodwill$155.59M$155.59M$155.59M$155.59M$155.59M$155.59M$155.59M$155.59M$155.59M$133.00M
Total assets$1.64B$2.30B$2.65B$3.43B$3.56B$4.93B$5.84B$6.78B$5.44B$6.96B
Total current liabilities$273.50M$375.40M$425.28M$513.34M$631.20M$854.31M$1.16B$1.24B$1.64B$1.52B
Long-term debt$749.80M$26.80M$19.09B———————
Total debt$749.80M$26.80M$19.09B———————
Total liabilities$1.22B$671.95M$719.79M$828.34M$949.65M$1.16B$1.47B$1.59B$2.00B$1.79B
Shareholders' equity$419.47M$1.63B$1.93B$2.60B$2.61B$3.77B$4.37B$5.19B$3.45B$5.17B

Cash flow

fiscal years · USD
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow$304.76M-$92.99M$336.23M$710.66M-$124.60M$749.49M$969.94M$496.49M$335.34M$1.41B
Capital expenditures$120.28M$111.02M$73.48M$78.06M$187.38M$181.01M$77.83M———
Free cash flow$184.48M-$204.01M$262.74M$632.59M-$311.98M$568.48M$892.11M$496.49M$335.34M$1.41B
Investing cash flow-$232.49M-$349.98M-$86.42M-$87.45M-$269.00M-$207.70M-$78.54M-$207.68M$157.52M-$102.61M
Financing cash flow$44.62M$690.21M$14.66M$45.71M$71.71M$6.18M-$794.00K-$20.03M-$2.02B$101.04M
Share buybacks——————$0$0$2.00B$0
Stock-based compensation$96.20M$133.06M$148.15M$166.59M$177.88M$183.01M$188.42M$215.89M$266.06M$249.35M
Depreciation & amortization$58.42M$52.18M$54.97M$54.53M$51.81M$57.84M$67.86M$82.66M$89.25M$93.29M

Quarterly figures are rebuilt from the year-to-date totals companies report — Q4 is the full year minus the first nine months, since no 10-Q is filed for it. Values are as filed; later restatements replace earlier ones. Fiscal years are labelled by the calendar year in which they end.